Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically.
Lonza provides the BioResearch market with the tools life science researchers use to develop and test therapeutics, from basic research to final product release. At the Cologne site, the business unit segment Lonza Pharma – Bioscience Solutions develops and commercializes non-viral gene transfer products for primary cells and hard-to-transfect cell lines. These cells are important model systems for both basic and clinical research as they more accurately reflect the condition and behavior of cells within an organism when compared to commonly used laboratory cell lines. With Lonza’s Nucleofector™ Technology, the functionality of different genes can be analyzed in biologically relevant cell types. These results are used to more efficiently identify new targets for pharmaceuticals and therapies. The Cologne site is also the base for parts of other Lonza businesses. The European Microbial Control sales team trades innovative, chemistry-based and related solutions to destroy or to selectively inhibit the growth of harmful microorganisms. Lonza’s Life Science Ingredients division promotes high quality health ingredients for the nutrition market as well as chemical intermediates, modern herbicides, insecticides, and fungicides for the agrochemical market.
Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange and secondary listed on the Singapore Exchange Securities Trading Limited (“SGX-ST”). In 2012, the company had sales of CHF 3.925 billion.